following an abbreviated submission
tiotropium/olodaterol (Spiolto® Respimat®) is accepted for use within NHS Scotland.
Indication under review: maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Spiolto® Respimat® should be used in patients for whom tiotropium and olodaterol are appropriate choices of antimuscarinic and long-acting beta2-agonist respectively.
Tiotropium/olodaterol (Spiolto® Respimat®) is available at a lower cost than the individual inhalers given separately.
Download detailed advice107KB (PDF)
- Medicine name:
- tiotropium/olodaterol (Spiolto Respimat)
- SMC ID:
- Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Respiratory system
- Submission type
- Date advice published:
- 09 November 2015